yattreblif
2021-10-28
Wow
Merck Projects Billions in Sales of Covid Antiviral Molnupiravir<blockquote>默克预计新冠抗病毒药物莫努匹拉韦的销售额将达到数十亿美元</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":854169852,"tweetId":"854169852","gmtCreate":1635428473107,"gmtModify":1635428513104,"author":{"id":4090156416829480,"idStr":"4090156416829480","authorId":4090156416829480,"authorIdStr":"4090156416829480","name":"yattreblif","avatar":"https://static.tigerbbs.com/0c09ba70f4dad4731020c2b9c484a4da","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":19,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/854169852","repostId":1152442963,"repostType":4,"repost":{"id":"1152442963","kind":"news","pubTimestamp":1635427505,"share":"https://www.laohu8.com/m/news/1152442963?lang=zh_CN&edition=full","pubTime":"2021-10-28 21:25","market":"us","language":"en","title":"Merck Projects Billions in Sales of Covid Antiviral Molnupiravir<blockquote>默克预计新冠抗病毒药物莫努匹拉韦的销售额将达到数十亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1152442963","media":"Bloomberg","summary":"(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much ","content":"<p>(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.</p><p><blockquote>（彭博社）——据默克公司称，到2022年，该公司备受关注的Covid-19抗病毒药物莫努匹拉韦的全球销售额可能高达70亿美元。</blockquote></p><p> The figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December, Chief Financial Officer Caroline Litchfield said early Thursday on a conference call. She projected at least $5 billion in sales by the end of next year, provided it’s cleared.</p><p><blockquote>首席财务官Caroline Litchfield周四早些时候在电话会议上表示，如果实验药物在12月获得批准，这一数字包括今年高达10亿美元的收入。她预计，如果获得批准，到明年年底销售额至少将达到50亿美元。</blockquote></p><p> Molnupiravir has become one of the most highly anticipated coronavirus medications, as the pill is relatively cheap to make and easy to transport. Merck has taken steps to make sure that the drug will be distributed widely, including in low-income countries.</p><p><blockquote>Molnupiravir已成为最受期待的冠状病毒药物之一，因为该药物制造相对便宜且易于运输。默克公司已采取措施确保该药物得到广泛分发，包括在低收入国家。</blockquote></p><p> The drugmaker raised its annual forecast as it reported quarterly profit and revenue that beat Wall Street’s expectations. Adjusted earnings for the year will be $5.65 to $5.70 a share, up from the earlier guidance of $5.47 to $5.57, the drugmaker said in a statement. Revenue will be $47.4 billion to $47.9 billion, compared with the earlier guidance that topped out at $47.4 billion. The projections don’t include potential molnupiravir sales.</p><p><blockquote>该制药商上调了年度预测，因为该公司公布的季度利润和收入超出了华尔街的预期。该制药商在一份声明中表示，今年调整后每股收益将为5.65美元至5.70美元，高于此前指引的5.47美元至5.57美元。收入将为474亿至479亿美元，而此前的指导最高为474亿美元。这些预测不包括莫努匹拉韦的潜在销售额。</blockquote></p><p> Quarterly adjusted earnings were $1.75 a share, beating analysts’ average estimate by 20 cents, according to a statement. Revenue was $13.2 billion, compared with Wall Street expectations of $12.3 billion.</p><p><blockquote>一份声明称，季度调整后每股收益为1.75美元，比分析师平均预期高出20美分。营收132亿美元，华尔街预期123亿美元。</blockquote></p><p> The shares rose 2% in premarket U.S. trading.</p><p><blockquote>该股在美国盘前交易中上涨2%。</blockquote></p><p> Merck and partner Ridgeback Biotherapeutics LP are seeking U.S. authorization of molnupiravir, their Covid antiviral. Merck said it plans to make at least 20 million treatment courses of the drug next year, on top of 10 million it expects to make by the end of 2021.</p><p><blockquote>默克公司和合作伙伴Ridgeback Biotherapeutics LP正在寻求美国对其新冠抗病毒药物molnupiravir的授权。默克表示，计划明年至少生产2000万个疗程的该药物，预计到2021年底将生产1000万个疗程。</blockquote></p><p> The drug may become one of Merck’s leading products. Merck’s blockbuster cancer drug Keytruda brought in more than $14 billion in sales last year, followed by the diabetes drug Januvia with around $5 billion and nearly $4 billion for HPV vaccine Gardasil.</p><p><blockquote>该药或将成为默沙东的主导产品之一。默克公司的重磅癌症药物Keytruda去年销售额超过140亿美元，其次是糖尿病药物Januvia，销售额约为50亿美元，HPV疫苗Gardasil销售额近40亿美元。</blockquote></p><p> Merck said vaccine revenue contributed to the third-quarter results. However, sales of its pneumococcal vaccine, Pneumovax 23, declined nearly 30%, “primarily driven by lower demand in the United States reflecting prioritization of the Covid-19 vaccine.”</p><p><blockquote>默沙东表示，疫苗收入为第三季度业绩做出了贡献。然而，其肺炎球菌疫苗Pneumovax 23的销售额下降了近30%，“主要是由于美国需求下降反映了Covid-19疫苗的优先考虑。”</blockquote></p><p> Sales of the papillomavirus vaccine Gardasil were $1.99 billion, topping estimates. Sales of blockbuster cancer drug Keytruda and the diabetes medications Januvia and Janumet also beat Wall Street projections. Animal health sales were $1.42 billion, in line with expectations.</p><p><blockquote>乳头瘤病毒疫苗Gardasil的销售额为19.9亿美元，超出预期。重磅癌症药物Keytruda以及糖尿病药物Januvia和Janumet的销售额也超出了华尔街的预期。动物保健销售额为14.2亿美元，符合预期。</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Projects Billions in Sales of Covid Antiviral Molnupiravir<blockquote>默克预计新冠抗病毒药物莫努匹拉韦的销售额将达到数十亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Projects Billions in Sales of Covid Antiviral Molnupiravir<blockquote>默克预计新冠抗病毒药物莫努匹拉韦的销售额将达到数十亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-10-28 21:25</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.</p><p><blockquote>（彭博社）——据默克公司称，到2022年，该公司备受关注的Covid-19抗病毒药物莫努匹拉韦的全球销售额可能高达70亿美元。</blockquote></p><p> The figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December, Chief Financial Officer Caroline Litchfield said early Thursday on a conference call. She projected at least $5 billion in sales by the end of next year, provided it’s cleared.</p><p><blockquote>首席财务官Caroline Litchfield周四早些时候在电话会议上表示，如果实验药物在12月获得批准，这一数字包括今年高达10亿美元的收入。她预计，如果获得批准，到明年年底销售额至少将达到50亿美元。</blockquote></p><p> Molnupiravir has become one of the most highly anticipated coronavirus medications, as the pill is relatively cheap to make and easy to transport. Merck has taken steps to make sure that the drug will be distributed widely, including in low-income countries.</p><p><blockquote>Molnupiravir已成为最受期待的冠状病毒药物之一，因为该药物制造相对便宜且易于运输。默克公司已采取措施确保该药物得到广泛分发，包括在低收入国家。</blockquote></p><p> The drugmaker raised its annual forecast as it reported quarterly profit and revenue that beat Wall Street’s expectations. Adjusted earnings for the year will be $5.65 to $5.70 a share, up from the earlier guidance of $5.47 to $5.57, the drugmaker said in a statement. Revenue will be $47.4 billion to $47.9 billion, compared with the earlier guidance that topped out at $47.4 billion. The projections don’t include potential molnupiravir sales.</p><p><blockquote>该制药商上调了年度预测，因为该公司公布的季度利润和收入超出了华尔街的预期。该制药商在一份声明中表示，今年调整后每股收益将为5.65美元至5.70美元，高于此前指引的5.47美元至5.57美元。收入将为474亿至479亿美元，而此前的指导最高为474亿美元。这些预测不包括莫努匹拉韦的潜在销售额。</blockquote></p><p> Quarterly adjusted earnings were $1.75 a share, beating analysts’ average estimate by 20 cents, according to a statement. Revenue was $13.2 billion, compared with Wall Street expectations of $12.3 billion.</p><p><blockquote>一份声明称，季度调整后每股收益为1.75美元，比分析师平均预期高出20美分。营收132亿美元，华尔街预期123亿美元。</blockquote></p><p> The shares rose 2% in premarket U.S. trading.</p><p><blockquote>该股在美国盘前交易中上涨2%。</blockquote></p><p> Merck and partner Ridgeback Biotherapeutics LP are seeking U.S. authorization of molnupiravir, their Covid antiviral. Merck said it plans to make at least 20 million treatment courses of the drug next year, on top of 10 million it expects to make by the end of 2021.</p><p><blockquote>默克公司和合作伙伴Ridgeback Biotherapeutics LP正在寻求美国对其新冠抗病毒药物molnupiravir的授权。默克表示，计划明年至少生产2000万个疗程的该药物，预计到2021年底将生产1000万个疗程。</blockquote></p><p> The drug may become one of Merck’s leading products. Merck’s blockbuster cancer drug Keytruda brought in more than $14 billion in sales last year, followed by the diabetes drug Januvia with around $5 billion and nearly $4 billion for HPV vaccine Gardasil.</p><p><blockquote>该药或将成为默沙东的主导产品之一。默克公司的重磅癌症药物Keytruda去年销售额超过140亿美元，其次是糖尿病药物Januvia，销售额约为50亿美元，HPV疫苗Gardasil销售额近40亿美元。</blockquote></p><p> Merck said vaccine revenue contributed to the third-quarter results. However, sales of its pneumococcal vaccine, Pneumovax 23, declined nearly 30%, “primarily driven by lower demand in the United States reflecting prioritization of the Covid-19 vaccine.”</p><p><blockquote>默沙东表示，疫苗收入为第三季度业绩做出了贡献。然而，其肺炎球菌疫苗Pneumovax 23的销售额下降了近30%，“主要是由于美国需求下降反映了Covid-19疫苗的优先考虑。”</blockquote></p><p> Sales of the papillomavirus vaccine Gardasil were $1.99 billion, topping estimates. Sales of blockbuster cancer drug Keytruda and the diabetes medications Januvia and Janumet also beat Wall Street projections. Animal health sales were $1.42 billion, in line with expectations.</p><p><blockquote>乳头瘤病毒疫苗Gardasil的销售额为19.9亿美元，超出预期。重磅癌症药物Keytruda以及糖尿病药物Januvia和Janumet的销售额也超出了华尔街的预期。动物保健销售额为14.2亿美元，符合预期。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/merck-raises-annual-forecast-profit-104849738.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/merck-raises-annual-forecast-profit-104849738.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1152442963","content_text":"(Bloomberg) -- Merck & Co.’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker.\nThe figure includes up to $1 billion in revenue this year if the experimental drug is authorized in December, Chief Financial Officer Caroline Litchfield said early Thursday on a conference call. She projected at least $5 billion in sales by the end of next year, provided it’s cleared.\nMolnupiravir has become one of the most highly anticipated coronavirus medications, as the pill is relatively cheap to make and easy to transport. Merck has taken steps to make sure that the drug will be distributed widely, including in low-income countries.\nThe drugmaker raised its annual forecast as it reported quarterly profit and revenue that beat Wall Street’s expectations. Adjusted earnings for the year will be $5.65 to $5.70 a share, up from the earlier guidance of $5.47 to $5.57, the drugmaker said in a statement. Revenue will be $47.4 billion to $47.9 billion, compared with the earlier guidance that topped out at $47.4 billion. The projections don’t include potential molnupiravir sales.\nQuarterly adjusted earnings were $1.75 a share, beating analysts’ average estimate by 20 cents, according to a statement. Revenue was $13.2 billion, compared with Wall Street expectations of $12.3 billion.\nThe shares rose 2% in premarket U.S. trading.\nMerck and partner Ridgeback Biotherapeutics LP are seeking U.S. authorization of molnupiravir, their Covid antiviral. Merck said it plans to make at least 20 million treatment courses of the drug next year, on top of 10 million it expects to make by the end of 2021.\nThe drug may become one of Merck’s leading products. Merck’s blockbuster cancer drug Keytruda brought in more than $14 billion in sales last year, followed by the diabetes drug Januvia with around $5 billion and nearly $4 billion for HPV vaccine Gardasil.\nMerck said vaccine revenue contributed to the third-quarter results. However, sales of its pneumococcal vaccine, Pneumovax 23, declined nearly 30%, “primarily driven by lower demand in the United States reflecting prioritization of the Covid-19 vaccine.”\nSales of the papillomavirus vaccine Gardasil were $1.99 billion, topping estimates. Sales of blockbuster cancer drug Keytruda and the diabetes medications Januvia and Janumet also beat Wall Street projections. Animal health sales were $1.42 billion, in line with expectations.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":511,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/854169852"}
精彩评论